Observational Study of Conjunctivitis in Dupixent Treatment for Atopic Dermatitis (H-47761)
It includes two groups of adults ages 18-65 with ongoing Dupixent therapy for atopic dermatitis for a minimum of eight weeks. Group 1 involves 3-4 adults with new onset of bilateral conjunctivitis or worsening condition since using therapy. Attend four ophthalmic clinic visits and post resolution check up over a six month period. Treated at the discretion of the eye surface expert. Group 2 involves 1-2 adults without signs or symptoms of ocular inflammation. Will undergo the same comprehensive assessment twice, 4 weeks apart.